BioStock: WntResearch hopes for in-depth talks about Foxy-5

Things are starting to move again for WntResearch, the company recently got the green light for its new study plan for Foxy-5. The company looks forward to being able to resume recruitment in its phase II study with the drug candidate. BioStock contacted CEO Pernilla Sandwall in connection with the release of the company’s report for the second quarter.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/08/wntresearch-hopes-for-in-depth-talks-about-foxy-5/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se